Isola Therapeutics (Isola) is a privately owned, preclinical stage biopharmaceutical and medical device company focused on developing endoluminal drug delivery solutions to treat life-threatening diseases, including cancer and acute respiratory conditions.  The goal of the proprietary drug delivery system is to maximize drug absorption throughout a treated hollow organ while minimizing off-target drug exposure.  Isola’s drug delivery systems are currently designed for pulmonary and gastrointestinal applications.  The company is led by seasoned industry veterans in collaboration with experienced partners who have developed and commercialized numerous innovative medical devices.